CYP3A5 *1 allele associated with tacrolimus trough concentrations but not subclinical acute rejection or chronic allograft nephropathy in Japanese renal transplant recipients

[21] van Schaik RH(1993)Pharmacokinetics of FK506 in liver transplant recipients after continuous intravenous infusion J Clin Pharmacol 33 606-611

[22] van der Heiden IP(2001)Chrono and clinical pharmacokinetic study of tacrolimus in continuous intravenous administration Int J Urol 8 353-358

[23] van der Werf M(2000)Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF dose-ranging kidney transplant study group Transplantation 69 875-880

[24] Gregoor PJ(2005)Predictors of renal allograft histologic damage progression J Am Soc Nephrol 16 817-824

[25] Lindemans J(2003)Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy Kidney Int 64 1027-1034

[26] Weimar W(2002)Genetic contribution to variable human CYP3A-mediated metabolism Adv Drug Delivery Rev 54 1271-1294

[27] van Gelder T(undefined)undefined undefined undefined undefined-undefined

[28] Haufroid V(undefined)undefined undefined undefined undefined-undefined

[29] Mourad M(undefined)undefined undefined undefined undefined-undefined

[30] Van Kerckhove V(undefined)undefined undefined undefined undefined-undefined

[21] van Schaik RH(1993)Pharmacokinetics of FK506 in liver transplant recipients after continuous intravenous infusion J Clin Pharmacol 33 606-611

[22] van der Heiden IP(2001)Chrono and clinical pharmacokinetic study of tacrolimus in continuous intravenous administration Int J Urol 8 353-358

[23] van der Werf M(2000)Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF dose-ranging kidney transplant study group Transplantation 69 875-880

[24] Gregoor PJ(2005)Predictors of renal allograft histologic damage progression J Am Soc Nephrol 16 817-824

[25] Lindemans J(2003)Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy Kidney Int 64 1027-1034

[26] Weimar W(2002)Genetic contribution to variable human CYP3A-mediated metabolism Adv Drug Delivery Rev 54 1271-1294

[27] van Gelder T(undefined)undefined undefined undefined undefined-undefined

[28] Haufroid V(undefined)undefined undefined undefined undefined-undefined

[29] Mourad M(undefined)undefined undefined undefined undefined-undefined

[30] Van Kerckhove V(undefined)undefined undefined undefined undefined-undefined